Sio Capital Management, LLC
13F Reported Value
ⓘ$604.3M
incl. option notional
Equity Holdings
ⓘ$583.5M
Option Notional
ⓘ$20.8M
$18.2M puts / $2.6M calls
Holdings
59
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Sio Capital Management, LLC disclosed 59 positions worth $604.3M in its Form 13F-HR for Q2 2026 — $583.5M in common stock plus $20.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $AVR (Anteris Technologies Global Corp.) at 9.4% of the equity portfolio, followed by $COR and $MMS. During the quarter the fund opened 16 new positions and exited 33 — including a new stake in $ALLO and a full exit from $CORT. The portfolio is most concentrated in Healthcare (76.2% of disclosed assets). All figures are sourced directly from Sio Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1482416.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $54.6M5,545,984 sh
- 61.1#807
Quality
$49.1M173,588 sh - 55.0#1,277
Quality
$38.5M715,267 sh - 33.9
Quality
$27.7M13,323,431 sh - 79.5
Quality
$23.8M301,816 sh - —
Quality
$22.9M436,700 sh - —
Quality
$22.2M695,315 sh - 65.5
Quality
$19.0M925,834 sh - $18.2M1,230,700 sh
- 36.1
Quality
$17.9M480,383 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Anteris Technologies Global Corp.$AVR | — | $54.6M | 5,545,984 |
 Cencora, Inc.$COR | 61.1#807 | $49.1M | 173,588 |
 MAXIMUS, INC.$MMS | 55.0#1,277 | $38.5M | 715,267 |
 Allogene Therapeutics, Inc.$ALLO | 33.9 | $27.7M | 13,323,431 |
 GLOBUS MEDICAL INC$GMED | 79.5 | $23.8M | 301,816 |
 GSK plc$GSK | — | $22.9M | 436,700 |
 Tyra Biosciences, Inc.$TYRA | — | $22.2M | 695,315 |
 Waystar Holding Corp.$WAY | 65.5 | $19.0M | 925,834 |
 SELLAS Life Sciences Group, Inc.$SLSPUT | — | $18.2M | 1,230,700 |
 IDEAYA Biosciences, Inc.$IDYA | 36.1 | $17.9M | 480,383 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Sio Capital Management, LLC's 59 positions.
Showing top 10 of 59 holdings.
Sector Allocation
Healthcare
$444.5M
Industrials
$53.0M
Consumer Staples
$49.1M
Technology
$37.0M
Full Holdings — Sio Capital Management, LLC (Q2 2026)
All 59 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AVR | Anteris Technologies Global Corp. | $54.6M | 9.4% | +3% | — |
| 2 | $COR | Cencora, Inc. | $49.1M | 8.4% | +72% | 61.1 |
| 3 | $MMS | MAXIMUS, INC. | $38.5M | 6.6% | -7% | 55 |
| 4 | $ALLO | Allogene Therapeutics, Inc. | $27.7M | 4.8% | NEW | 33.9 |
| 5 | $GMED | GLOBUS MEDICAL INC | $23.8M | 4.1% | NEW | 79.5 |
| 6 | $GSK | GSK plc | $22.9M | 3.9% | +13% | — |
| 7 | $TYRA | Tyra Biosciences, Inc. | $22.2M | 3.8% | +15% | — |
| 8 | $WAY | Waystar Holding Corp. | $19.0M | 3.3% | -44% | 65.5 |
| 9 | $SLSPUT | SELLAS Life Sciences Group, Inc. | $18.2M | — | NEW | — |
| 10 | $IDYA | IDEAYA Biosciences, Inc. | $17.9M | 3.1% | NEW | 36.1 |
| 11 |  $ORKA | Oruka Therapeutics, Inc. | $16.9M | 2.9% | +34% | — |
| 12 |  $CI | Cigna Group | $15.9M | 2.7% | NEW | 66.2 |
| 13 |  $SNY | Sanofi | $15.5M | 2.7% | +52% | — |
| 14 |  $ICLR | ICON PLC | $15.3M | 2.6% | -71% | — |
| 15 |  $VTRS | Viatris Inc | $15.2M | 2.6% | NEW | 45.4 |
| 16 |  $CCRN | CROSS COUNTRY HEALTHCARE INC | $14.5M | 2.5% | +0% | 26.6 |
| 17 |  $RAPP | Rapport Therapeutics, Inc. | $12.8M | 2.2% | -16% | — |
| 18 |  $ABT | ABBOTT LABORATORIES | $11.7M | 2.0% | -31% | 65.5 |
| 19 |  $CELC | Celcuity Inc. | $11.5M | 2.0% | -43% | — |
| 20 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $11.3M | 1.9% | +110% | 65.7 |
| 21 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $11.2M | 1.9% | NEW | 71 |
| 22 |  $BMY | BRISTOL MYERS SQUIBB CO | $11.1M | 1.9% | NEW | 70.4 |
| 23 |  $MDT | Medtronic plc | $11.1M | 1.9% | NEW | 68.7 |
| 24 |  $VIR | Vir Biotechnology, Inc. | $11.0M | 1.9% | -28% | 38.2 |
| 25 |  $SENS | Senseonics Holdings, Inc. | $9.0M | 1.6% | +1276% | 27.7 |
| 26 |  $EYPT | EyePoint, Inc. | $8.9M | 1.5% | -14% | 3.5 |
| 27 |  $HELP | CYBIN INC. | $8.6M | 1.5% | NEW | — |
| 28 |  $ANIP | ANI PHARMACEUTICALS INC | $8.1M | 1.4% | -63% | 72.5 |
| 29 |  $TARA | Protara Therapeutics, Inc. | $7.3M | 1.3% | -2% | — |
| 30 |  $RLMD | RELMADA THERAPEUTICS, INC. | $6.9M | 1.2% | +4% | — |
| 31 |  $TNGX | Tango Therapeutics, Inc. | $6.5M | 1.1% | NEW | 17.6 |
| 32 |  $AQST | Aquestive Therapeutics, Inc. | $6.2M | 1.1% | -23% | 14.5 |
| 33 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.8M | 1.0% | -84% | 22.6 |
| 34 |  $SION | Sionna Therapeutics, Inc. | $5.6M | 1.0% | -57% | — |
| 35 |  $OCUL | OCULAR THERAPEUTIX, INC | $5.3M | 0.9% | -44% | 8.4 |
| 36 |  $ZBIO | Zenas BioPharma, Inc. | $5.3M | 0.9% | -37% | 7.4 |
| 37 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $5.2M | 0.9% | -14% | — |
| 38 |  $OKUR | OnKure Therapeutics, Inc. | $4.9M | 0.8% | +0% | — |
| 39 |  $SVRA | Savara Inc | $3.8M | 0.7% | +1% | — |
| 40 |  $PMVP | PMV Pharmaceuticals, Inc. | $3.5M | 0.6% | -14% | — |
| 41 |  $AVAH | Aveanna Healthcare Holdings, Inc. | $3.2M | 0.5% | NEW | 65.6 |
| 42 |  $OVID | Ovid Therapeutics Inc. | $2.7M | 0.5% | -20% | 26.4 |
| 43 |  $IMNM | Immunome Inc. | $2.6M | 0.5% | -25% | 25.3 |
| 44 |  $HIMSCALL | Hims & Hers Health, Inc. | $2.6M | — | NEW | 53.4 |
| 45 |  $ANTX | AN2 Therapeutics, Inc. | $2.6M | 0.4% | -19% | — |
| 46 |  $SER | Serina Therapeutics, Inc. | $1.9M | 0.3% | +0% | — |
| 47 |  $ALGS | Aligos Therapeutics, Inc. | $1.9M | 0.3% | +0% | — |
| 48 |  $IBIO | iBio, Inc. | $1.6M | 0.3% | +0% | 10.4 |
| 49 |  $XLO | Xilio Therapeutics, Inc. | $1.5M | 0.3% | +0% | 35.6 |
| 50 |  $AORT | ARTIVION, INC. | $1.1M | 0.2% | NEW | 48.1 |
| 51 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $995,385 | 0.2% | +0% | — |
| 52 |  $TELA | TELA Bio, Inc. | $477,225 | 0.1% | +0% | 25.2 |
| 53 |  $ADGM | Adagio Medical Holdings, Inc. | $455,461 | 0.1% | -46% | — |
| 54 |  $NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | $251,612 | 0.0% | -83% | — |
| 55 |  $ENVB | Enveric Biosciences, Inc. | $248,400 | 0.0% | NEW | — |
| 56 |  $MODD | Modular Medical, Inc. | $117,855 | 0.0% | +0% | — |
| 57 |  $QTI | QT IMAGING HOLDINGS, INC. | $62,011 | 0.0% | NEW | — |
| 58 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $1,480 | 0.0% | +0% | — |
| 59 |  $HUMA | Humacyte, Inc. | $477 | 0.0% | +0% | 9.1 |
New Positions (16)
$ALLO Allogene Therapeutics, Inc.$27.7M$GMED GLOBUS MEDICAL INC$23.8M$SLSPUT SELLAS Life Sciences Group, Inc.$18.2M$IDYA IDEAYA Biosciences, Inc.$17.9M$CI Cigna Group$15.9M$VTRS Viatris Inc$15.2M$REGN REGENERON PHARMACEUTICALS, INC.$11.2M$BMY BRISTOL MYERS SQUIBB CO$11.1M$MDT Medtronic plc$11.1M$HELP CYBIN INC.$8.6M$TNGX Tango Therapeutics, Inc.$6.5M$AVAH Aveanna Healthcare Holdings, Inc.$3.2M$HIMSCALL Hims & Hers Health, Inc.$2.6M$AORT ARTIVION, INC.$1.1M$ENVB Enveric Biosciences, Inc.$248,400Exited Positions (33)
$CORT CORCEPT THERAPEUTICS INC
$LIVN LivaNova PLC
$EMBC Embecta Corp.
$ABVX Abivax S.A.
$HAE HAEMONETICS CORP
$TFX TELEFLEX INC
$BMRN BIOMARIN PHARMACEUTICAL INC
$GPCR Structure Therapeutics Inc.
$BHVN Biohaven Ltd.
$MNPR Monopar Therapeutics
$CRNX Crinetics Pharmaceuticals, Inc.
$EWTX Edgewise Therapeutics, Inc.
$CMPS COMPASS Pathways plc
$QDEL QuidelOrtho Corp
$REPL Replimune Group, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Sio Capital Management, LLC including:
Track Sio Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Sio Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Sio Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Sio Capital Management, LLC (SEC CIK: 1482416), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Sio Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.